CSL Ltd (ASX: CSL) shares are trading around $177, a long way below their 52-week peak of $282.20. For a biotech that has been one of the ASX's great long-term compounders, that kind of fall naturally raises a big question. Is this a genuine buying opportunity, or is the market telling us something has changed?
To answer that properly, you need to understand why the shares fell in the first place.
Image source: Getty Images
Why CSL shares declined so sharply
The sell-off has not been driven by a single issue, but by a cluster of disappointments that arrived at the same time.
The most important has been pressure on plasma margins. Plasma collection costs rose significantly after COVID as CSL worked to rebuild supply, while broader inflation lifted operating costs. Volumes recovered, but profitability lagged expectations, which mattered because CSL had historically delivered very reliable margin expansion.
Within that, the market was particularly disappointed with CSL Behring. This division had been positioned as the engine room of long-term growth, especially through immunoglobulins. Instead, growth slowed materially. That was a shock relative to expectations for steady, high-quality growth.
The Seqirus business also weighed on sentiment. Influenza vaccine demand, particularly in the US, proved weaker and more volatile than expected. That hurt earnings and challenged the view that vaccines would provide smoother diversification alongside plasma.
Guidance cuts compounded the problem. Investors had already lowered expectations once, only to see them revised down again. That sequence matters because it impacts confidence in near-term execution even if the long-term strategy remains intact.
There were also regional and narrative overhangs. Albumin demand in China became less predictable, adding uncertainty at an awkward time. Meanwhile, the longer-term gene therapy discussion resurfaced, not because it is an immediate threat, but because it gave investors another reason to question long-run assumptions.
What looks different at $177
At $177, expectations are far lower than they were when CSL traded above $250. The share price now reflects slower near-term growth, a gradual margin recovery rather than a rapid one, and more conservative assumptions around vaccines and China.
Importantly, the core business has not broken. CSL remains one of just a handful of global plasma leaders, operating in a highly consolidated market with significant barriers to entry. Plasma demand trends have not disappeared, and management continues to point to efficiency initiatives that should support margin recovery over time.
This means CSL does not need everything to go right to justify a higher share price. It simply needs fewer things to go wrong.
So, are CSL shares still a bargain?
I would not describe CSL shares at $177 as risk-free. Execution still matters, and patience is required. But relative to where expectations were at the peak, the risk-reward now looks far more balanced.
The share price decline has been driven more by disappointment and valuation reset than by a permanent deterioration in the business. If margins stabilise, earnings growth improves modestly, and confidence slowly rebuilds. CSL does not need to return to peak optimism to deliver respectable returns from here.
At $177, I think there is a credible case that CSL shares are a bargain for long-term investors willing to tolerate near-term uncertainty while waiting for the fundamentals to catch up.
